ENDRA Life Sciences Inc.

NASDAQ: NDRA · Healthcare · Medical - Diagnostics & Research

PublicHQ Ann Arbor, MI · WashtenawCIK 0001681682Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

26D

FH 23DQ 23GM 31SS 41

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, growth stability · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$7.0M

Employees

Market cap

$3.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02020

Net income-$7.0M-$7.0M2025

Operating income-$5.8M-$5.8M2025

Total assets$3.9M$3.9M2025

Liabilities$1.6M$1.6M2025

Equity$2.3M$2.3M2025

Revenue trend

FY2017 – FY2020 · USD

$515.6k

FY17

$351.6k

FY18

$6.2k

FY18

FY19

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

ENDRA Life Sciences Inc. booked $0 in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

NuGen Medical Devices Inc.24D Enzolytics Inc.——Matinas BioPharma Holdings, Inc.32D Avricore Health Inc.——

Neighbors

Washtenaw →

Domino's Pizza, Inc.$4.9B74B Esperion Therapeutics, Inc.$403.1M60C Kraig Biocraft Laboratories, Inc.$401.6k23D University Bancorp, Inc.——The Coretec Group Inc.$0——

Key facts

CEOAlexander Y. Tokman

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersAnn Arbor, MI

ExchangeNASDAQ: NDRA

Employees21

IPO date2017-06-30

Latest filings

8-K2026-07-09 8-K2026-06-26 8-K2026-06-25 8-K2026-05-28 10-Q2026-05-15 8-K2026-04-21 8-K2026-03-31 10-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.